Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study

Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases

(2017) Leon A Adams et al.   GUT

Novel antidiabetic medications for non-alcoholic fatty liver disease with type 2 diabetes mellitus

(2017) Yoshio Sumida et al.   HEPATOLOGY RESEARCH

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

(2017) Bruce Neal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mitochondrial Adaptation in Nonalcoholic Fatty Liver Disease: Novel Mechanisms and Treatment Strategies

(2017) Nishanth E. Sunny et al.   TRENDS IN ENDOCRINOLOGY AND METABOLISM

Renal, metabolic and cardiovascular considerations of SGLT2 inhibition

(2016) Ralph A. DeFronzo et al.   Nature Reviews Nephrology

Adaptation of Hepatic Mitochondrial Function in Humans with Non-Alcoholic Fatty Liver Is Lost in Steatohepatitis

(2015) Chrysi Koliaki et al.   Cell Metabolism

Nonalcoholic Fatty Liver Disease

(2015) Mary E. Rinella   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Double-blind Randomized Placebo-controlled Clinical Trial of Omega 3 Fatty Acids for the Treatment of Diabetic Patients With Nonalcoholic Steatohepatitis

(2015) Srinivasan Dasarathy et al.   JOURNAL OF CLINICAL GASTROENTEROLOGY

Effects of n-3 fish oil on metabolic and histological parameters in NASH: A double-blind, randomized, placebo-controlled trial

(2015) Curtis K. Argo et al.   JOURNAL OF HEPATOLOGY

Treating liver fat and serum triglyceride levels in NAFLD, effects of PNPLA3 and TM6SF2 genotypes: Results from the WELCOME trial

(2015) Eleonora Scorletti et al.   JOURNAL OF HEPATOLOGY

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial

(2015) Brent A Neuschwander-Tetri et al.   LANCET

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

(2015) Bernard Zinman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy of poly-unsaturated fatty acid therapy on patients with nonalcoholic steatohepatitis

(2015) Yun-Hua Li et al.   WORLD JOURNAL OF GASTROENTEROLOGY

No Significant Effects of Ethyl-Eicosapentanoic Acid on Histologic Features of Nonalcoholic Steatohepatitis in a Phase 2 Trial

(2014) Arun J. Sanyal et al.   GASTROENTEROLOGY

Fibroblast Growth Factor 21 Is Regulated by the IRE1α-XBP1 Branch of the Unfolded Protein Response and Counteracts Endoplasmic Reticulum Stress-induced Hepatic Steatosis

(2014) Shan Jiang et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients

(2014) Ele Ferrannini et al.   JOURNAL OF CLINICAL INVESTIGATION

PNPLA3gene polymorphism and response to lifestyle modification in patients with nonalcoholic fatty liver disease

(2014) Jiayun Shen et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Characteristics of hepatic fatty acid compositions in patients with nonalcoholic steatohepatitis

(2014) Kazutoshi Yamada et al.   LIVER INTERNATIONAL

Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin

(2013) J. Bolinder et al.   DIABETES OBESITY & METABOLISM

Changes in Insulin Sensitivity and Insulin Secretion with the Sodium Glucose Cotransporter 2 Inhibitor Dapagliflozin

(2013) Sunder Mudaliar et al.   Diabetes Technology & Therapeutics

Circulating Levels of FGF-21 in Obese Youth: Associations With Liver Fat Content and Markers of Liver Damage

(2013) Cosimo Giannini et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Effects of n-6 PUFAs compared with SFAs on liver fat, lipoproteins, and inflammation in abdominal obesity: a randomized controlled trial

(2012) Helena Bjermo et al.   AMERICAN JOURNAL OF CLINICAL NUTRITION

A novel omega-3 free fatty acid formulation has dramatically improved bioavailability during a low-fat diet compared with omega-3-acid ethyl esters: The ECLIPSE (Epanova® compared to Lovaza® in a pharmacokinetic single-dose evaluation) study

(2012) Michael H. Davidson et al.   Journal of Clinical Lipidology

High serum level of fibroblast growth factor 21 is an independent predictor of non-alcoholic fatty liver disease: A 3-year prospective study in China

(2012) Huating Li et al.   JOURNAL OF HEPATOLOGY

Omega-3 supplementation and non-alcoholic fatty liver disease: A systematic review and meta-analysis

(2011) Helen M. Parker et al.   JOURNAL OF HEPATOLOGY

Plasma Acylcarnitine Profiles Suggest Incomplete Long-Chain Fatty Acid β-Oxidation and Altered Tricarboxylic Acid Cycle Activity in Type 2 Diabetic African-American Women

(2009) Sean H. Adams et al.   JOURNAL OF NUTRITION

Mitochondrial Overload and Incomplete Fatty Acid Oxidation Contribute to Skeletal Muscle Insulin Resistance

(2008) Timothy R. Koves et al.   Cell Metabolism

Hepatic Stearoyl-CoA Desaturase (SCD)-1 Activity and Diacylglycerol but Not Ceramide Concentrations Are Increased in the Nonalcoholic Human Fatty Liver

(2008) A. Kotronen et al.   DIABETES

Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease

(2008) Stefano Romeo et al.   NATURE GENETICS

PPARα regulates the hepatotoxic biomarker alanine aminotransferase (ALT1) gene expression in human hepatocytes

(2008) Petra Thulin et al.   TOXICOLOGY AND APPLIED PHARMACOLOGY